| 7/19/2021 |
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Icon (NASDAQ: ICLR) |
analystratings.com |
... Biogen ( BIIB – Research Report ) and Icon ( ICLR – https://www.tipranks.com/subscribe/research-report/?symbol=iclr&ref=AR_STOCK&refersTo=&merge=AnalystRatings ) with bullish sentiments. Biogen (BIIB) In a report issued on July 16, Umer Raffat from Evercore ISI maintained a Buy rating on Biogen. The company’s shares closed last Friday at $324.62. According to TipRanks.com , Raffat is a 1-star analyst with an average return of 0.0% and ... |
| 7/5/2021 |
Evercore ISI Reaffirms Their Buy Rating on CureVac (CVAC) |
analystratings.com |
Evercore ISI Reaffirms Their Buy Rating on CureVac (CVAC) [Carrie Williams] Evercore ISI analyst Umer Raffat maintained a Buy rating on CureVac ( CVAC – Research Report ) on July 2. The company’s shares closed last Friday at $64.76. According to TipRanks.com , Raffat is a 2-star analyst with an average return of 1.9% and a 54.7% success rate. Raffat covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals ... |
| 6/16/2021 |
KIN Stock Rockets On Elanco's $440 Million Buyout; Can They Take On Zoetis? | Investor's Business Daily |
investors.com |
... also gained some ground.X The deal adds three potential blockbuster drugs to Elanco's pipeline. The development-stage drugs are in the growing dermatology segment. Zoetis sells two lucrative eczema treatments, Evercore ISI analyst Umer Raffat said in a report to clients."The core thesis on Elanco is that their growth trajectory is set to accelerate into 2023," he said. "And today's deal just amplified that 2023-plus growth thesis ... |
| 6/16/2021 |
New Alzheimer's treatment Aduhelm may be too costly for many seniors, deepening inequities | Business |
arcamax.com |
... works and if the drug, which must be infused at a medical office, is worth the substantial side effects.During a conference call with investment analysts, Biogen's chief executive defended the drug's cost when Umer Raffat , of Evercore ISI Institutional Equities, asked about a disconnect between the price and "the words that you've shared in your press releases like 'responsibility,' 'access,' 'health equity.'""We believe that the price is substantiated ... |
| 6/8/2021 |
Biogen faces tough questions over $56K a year price of newly approved Alzheimer's drug |
CNBC |
... we were at $10k) the sticker shock could further invigorate scrutiny on drug pricing," Stifel analyst Jeff Preis told investors in a note Monday.On a call with investors Tuesday morning, Evercore ISI analyst Umer Raffat congratulated the Massachusetts-based company on the drug's U.S. approval before asking executives to explain its price."I do think there's a disconnect between some of the words that you've shared in your press ... |
| 6/2/2021 |
CureVac (CVAC) Receives a Buy from Evercore ISI |
markets.co |
Christine Brown Healthcare Leave a commentIn a report released yesterday, Umer Raffat from Evercore ISI maintained a Buy rating on CureVac ( CVAC – Research Report ). $108.28. Raffat is a 2-star 1.9% and a 51.0% success rate. Raffat covers the Healthcare Phathom Pharmaceuticals, Mirati Therapeutics, and Kodiak Sciences.CureVac has an analyst consensus of Moderate Buy, with a price target consensus of $123.00, a 16.7% upside from current levels ... |
| 5/11/2021 |
Mirati Therapeutics (MRTX) Received its Third Buy in a Row |
markets.co |
Mirati Therapeutics (MRTX) Received its Third Buy in a Row Brian Anderson - May 11, 2021, 5:46 AM EDT SHARE ON:After H.C. Wainwright and J.P. Morgan gave Mirati Therapeutics (NASDAQ: MRTX ) a Buy rating last month, the company received another Buy, this time from Evercore ISI. Analyst Umer Raffat maintained a Buy rating on Mirati Therapeutics yesterday. $147.63. Raffat is a 2-star analyst with an average return of 1.0 ... |
| 5/6/2021 |
Asian Vaccine Makers’ Shares Slammed as U.S. Backs IP Waiver |
Yahoo News |
... announcement. The Biden administration’s plans will only open up a negotiation at the WTO and other countries and members remain unwilling, said Barclays analyst Carter Gould in a note.For Evercore ISI analyst Umer Raffat , U.S. support didn’t mean it was a “100% done deal” as other countries are also opposed. It “remains to be seen if U.S. leadership’s position sways others,” Raffat wrote in ... |
| 5/6/2021 |
Asian Vaccine Makers’ Shares Slammed as U.S. Backs IP Waiver |
Yahoo News |
... announcement. The Biden administration’s plans will only open up a negotiation at the WTO and other countries and members remain unwilling, said Barclays analyst Carter Gould in a note.For Evercore ISI analyst Umer Raffat , U.S. support didn’t mean it was a “100% done deal” as other countries are also opposed. It “remains to be seen if U.S. leadership’s position sways others,” Raffat wrote in ... |
| 4/29/2021 |
Evercore ISI Reaffirms Their Buy Rating on Amgen (AMGN) |
analystratings.com |
By Jason CarrIn a report released yesterday, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen ( AMGN – Research Report ). $236.71. Raffat is a 2- 2.9% and a 51.1% success rate. Raffat covers the Healthcare Kodiak Sciences, Vor Biopharma, and Athenex.Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $250.24, a 3.6% upside from current levels. In a report issued on ... |
| 4/29/2021 |
Merck & Co., Inc. (MRK) Q1 2021 Earnings Call Transcript |
alphastreet.com |
... President and President, Human Health Caroline Litchfield — Executive Vice President and Chief Financial Officer Dean Y. Li — Executive Vice President and President, Merck Research Laboratories Terence Flynn — Goldman Sachs — Analyst Umer Raffat — Evercore ISI — Analyst Chris Schott — J.P. Morgan — Analyst Andrew Baum — Citigroup — Analyst Geoff Meacham — Bank of America — Analyst Ronny Gal — Bernstein — Analyst Luisa Hector ... |
| 4/28/2021 |
Amgen Inc. (AMGN) Q1 2021 Earnings Call Transcript |
alphastreet.com |
... Michael Yee — Jefferies — Analyst Jay Olson — Oppenheimer — Analyst Matthew Harrison — Morgan Stanley — Analyst Yaron Werber — Cowen and Company — Analyst Terence Flynn — Goldman Sachs — Analyst Umer Raffat — Evercore ISI — Analyst Mohit Bansal — Citi — Analyst Geoffrey Porges — SVB Leerink — Analyst Alethia Young — Cantor Fitzgerald — Analyst Dane Leone — Raymond James — Analyst Ronny Gal ... |
| 4/27/2021 |
Eli Lilly and Company (LLY) Q1 2021 Earnings Call Transcript |
alphastreet.com |
... Research — Analyst Andrew Baum — Citigroup — Analyst Steve Scala — Cowen — Analyst Terence Flynn — Goldman Sachs — Analyst Ronny Gal — Bernstein — Analyst Kerry Holford — Berenberg — Analyst Umer Raffat — Evercore — Analyst Gregg Gilbert — Truist Securities — Analyst Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q1 2021 Earnings Conference Call. [Operator Instructions] As a ... |
| 4/22/2021 |
Biogen Inc. (BIIB) Q1 2021 Earnings Call Transcript |
alphastreet.com |
... and Development Michael McDonnell — Chief Financial Officer Michael Yee — Jefferies — Analyst Ronny Gal — Bernstein — Analyst Marc Goodman — SVB Leerink — Analyst Yatin Suneja — Guggenheim Partners — Analyst Umer Raffat — Evercore — Analyst Matthew Harrison — Morgan Stanley — Analyst Brian Abrahams — RBC Capital Markets — Analyst Colin Bristow — UBS — Analyst Evan Seigerman — Credit Suisse — Analyst Jay Olson ... |
| 12/4/2020 |
Investors send Bristol Myers' CVR soaring on rekindled hopes for timely CAR-T site inspection |
FiercePharma |
... company’s CEO, Scott Koenig, said at Evercore ISI’s annual HealthCONx event Wednesday.The site belongs to contract manufacturer AGC Biologics in Seattle, and the inspection was conducted in person, Evercore ISI analyst Umer Raffat wrote in an investor note Thursday. The CDMO didn’t immediately respond to a Fierce Pharma request for confirmation.By itself, the drug isn’t the most important candidate in Macrogenics’ portfolio, according ... |
| 11/25/2020 |
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference |
ask.com |
... antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 from 10:55 AM – 11:15 AM EST.Dr. Buell will provide an update on clinical programs, including AGEN1181, and corporate progress ... |
| 11/23/2020 |
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences |
BioSpace |
... it will present and participate at the following virtual conferences in December:Evercore ISI 3 rd Annual HealthCONx Conference Fireside chat and an open Q&A: Thursday, December 3, 2020 , 8 a.m. EST Moderator: Umer Raffat , Equity Research – Biotech-large, Pharma-major, Specialty Pharma Speaker: Dror Ben-Asher , CEO & Gilead Raday , Chief Operating OfficerPiper Sandler 32 nd Annual Virtual Healthcare Conference Fireside chat: Available on-demand from November ... |
| 11/17/2020 |
FDA unexpectedly rejects Alkermes schizophrenia drug, citing manufacturing concerns |
biopharmadive.com |
... because of the coronavirus epidemic.Any "slight issues" in manufacturing might generate a rejection instead of an approval, with the FDA failing to ask for clarification during a remote review process, Evercore ISI analyst Umer Raffat wrote in a note to investors.In the case of Alkermes, regulators conducted a remote review of records, confirmed receipt of information they requested from the company on Sept. 11 and then didn't provide ... |
| 11/10/2020 |
Amgen's asthma drug delivers a needed win |
biopharmadive.com |
... Amgen's tezepelumab showed significant reductions in asthma exacerbations — sometimes called asthma attacks — compared to those who got a placebo. More detailed data will be presented at an upcoming medical meeting, Amgen said. Umer Raffat , an analyst at Evercore ISI, called the results a "best-case outcome" for Amgen and tezepelumab, especially considering the drug had failed as an eczema treatment a few years back. "I expect Amgen to ... |
| 11/3/2020 |
Bausch Health Companies Inc. (BHC) Q3 2020 Earnings Call Transcript |
alphastreet.com |
... in order to continue to build what we hope will be a best-in-class product for the contact lens wearers through the SiHy Daily.Operator, next question, please.Our next question comes from Umer Raffat with Evercore. Please go ahead.Umer Raffat — Evercore ISI — AnalystHi. Thanks so much for taking my questions. I think perhaps the first one is the obvious one from the Print, which ... |